VIPIN RAMPRASAD LOHIYA
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology FAYETTEVILLE, GA NPI 1013295922
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology GA Gilead Sciences, Inc. All categories
General Payments — all program years on this page
$10,747.46
- Category: General Payments
- Program years: PY2018–2024
- Record count: 474
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,450.03 across 62 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,375.66 | 58 |
| Education | $74.37 | 4 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $219.59 | 5 |
| ABBVIE INC. | $188.09 | 9 |
| Regeneron Healthcare Solutions, Inc. | $144.72 | 6 |
| EISAI INC. | $75.93 | 4 |
| Genentech USA, Inc. | $74.70 | 3 |
| PFIZER INC. | $58.56 | 3 |
| Alexion Pharmaceuticals, Inc. | $57.96 | 3 |
| Janssen Biotech, Inc. | $56.91 | 3 |
| TerSera Therapeutics LLC | $49.69 | 2 |
| Merck Sharp & Dohme Corporation | $48.85 | 2 |
| BeiGene USA, Inc. | $47.23 | 2 |
| Janssen Pharmaceuticals, Inc | $44.00 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $42.18 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $37.66 | 2 |
| Acerta Pharma LLC | $33.58 | 2 |
| EMD Serono, Inc. | $29.94 | 1 |
| CSL Behring | $29.75 | 1 |
| Stemline Therapeutics Inc. | $29.36 | 1 |
| Daiichi Sankyo Inc. | $26.24 | 1 |
| ADC Therapeutics America, Inc. | $25.79 | 1 |
| SOBI, INC | $24.38 | 1 |
| SpringWorks Therapeutics, Inc. | $22.71 | 1 |
| Exelixis Inc. | $19.32 | 1 |
| Kyowa Kirin, Inc. | $17.68 | 1 |
| E.R. Squibb & Sons, L.L.C. | $16.32 | 1 |
| SERVIER PHARMACEUTICALS LLC | $15.07 | 1 |
| Dendreon Pharmaceuticals LLC | $13.82 | 1 |
By program year
Records — PY2024 (62)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.